Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK interaction of intravenous OPC-61815 with rifampicin in healthy Japanese males
jRCT2080224955Phase 1Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Nov 2019
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tolvaptan sodium phosphate (2 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Pharmacokinetics of OPC-61815 with and without rifampicin. Started Nov 2019; status: completed.
02
Drugs
tolvaptan sodium phosphate
Beyond the preview
Go deeper on jRCT2080224955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224955.